TRACLEER 62.5 MG

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

BOSENTAN AS MONOHYDRATE

متاح من:

J-C HEALTH CARE LTD

ATC رمز:

C02KX01

الشكل الصيدلاني:

FILM COATED TABLETS

تركيب:

BOSENTAN AS MONOHYDRATE 62.5 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

ACTELION PHARMACEUTICALS LTD., SWITZERLAND

المجموعة العلاجية:

BOSENTAN

المجال العلاجي:

BOSENTAN

الخصائص العلاجية:

Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV.Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease.

تاريخ الترخيص:

2022-05-31

خصائص المنتج

1
Tracleer 62.5 mg and Tracleer 125 mg_PI_ December-2023
TRACLEER
®
PRESCRIBING INFORMATION
1.
NAME OF THE MEDICINAL PRODUCT
Tracleer 62.5 mg film-coated tablets
Tracleer 125 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Tracleer 62.5 mg film-coated tablets
Each film-coated tablet contains 62.5 mg bosentan (as monohydrate).
Tracleer 125 mg film-coated tablets
Each film-coated tablet contains 125 mg bosentan (as monohydrate).
Excipient with known effect
This medicine contains less than 1 mmol sodium (23 mg) per tablet,
that is to
sayessentially ‘sodium-free’
.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablets):
Tracleer 62.5 mg film-coated tablets
Orange-white, round, biconvex, film-coated tablets, embossed with
“62.5” on one
side.
Tracleer 125 mg film-coated tablets
Orange-white, oval, biconvex, film-coated tablets, embossed with
“125” on one side.
Patient Alert Card
The marketing of Tracleer is subject to a risk management plan (RMP)
including
'Patient Alert Card'. The 'Patient Alert Card' emphasizes important
safety information
that the patient should be aware of before and during treatment. The
Patient Alert
Card is included in the pack, please explain to the patient the need
to review the card
before starting treatment.
WARNING: EMBRYO-FETAL TOXICITY
Do not administer Tracleer to a pregnant female because it may cause
fetal harm [see
Contraindications (4.3) and Fertility, pregnancy and lactation (4.6)].
Females of reproductive potential: Exclude pregnancy before the start
of treatment, monthly
during treatment, and 1 month after stopping treatment. Prevent
pregnancy during treatment and
for one month after stopping treatment by using acceptable methods of
contraception [see
Fertility, pregnancy and lactation (4.6)].
2
Tracleer 62.5 mg and Tracleer 125 mg_PI_ December-2023
4.
CLINICAL PARTICULARS
4.1
Therapeutic indications
Treatment of pulmonary arterial hypertension (PAH) in patients of WHO
functional
class II-IV.
Reductio